Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Macimorelin (Macrilen) vs Pasireotide (Signifor)
An educational, source-based comparison of Macimorelin (Macrilen) and Pasireotide (Signifor) — how each peptide works, what it's researched for, and what to know before going deeper.
Oral ghrelin agonist for diagnosing adult growth hormone deficiency.
Oral ghrelin receptor (GHSR-1a) agonist that stimulates pituitary GH release; peak GH response is measured to evaluate adult GH deficiency.
- Diagnostic test for adult GH deficiency
- • FDA-approved.
- • Avoid with QT-prolonging drugs.
- • Hold strong CYP3A4 inducers prior to test.
Multi-receptor somatostatin analog for Cushing's disease and acromegaly.
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.
- Cushing's disease
- Acromegaly (LAR formulation)
- • FDA-approved.
- • Significant hyperglycemia risk requires glucose monitoring.
- • Bradycardia and QT prolongation possible.
Macimorelin (Macrilen) vs Pasireotide (Signifor) — Key differences
- Class: Macimorelin (Macrilen) is classified as GH Secretagogue · Diagnostics, while Pasireotide (Signifor) is Somatostatin Analog · Endocrine.
- Primary research focus: Macimorelin (Macrilen) — diagnostic test for adult gh deficiency; Pasireotide (Signifor) — cushing's disease.
- Tag: FDA-Approved · Diagnostics vs FDA-Approved · Endocrine.